Technical Analysis for IPA - ImmunoPrecise Antibodies Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Expansion Breakdown | Bearish Swing Setup | -2.46% | |
| Bollinger Band Squeeze | Range Contraction | -2.46% | |
| BB Squeeze + Lower Band Touch | Range Contraction | -2.46% | |
| Gapped Up | Strength | -2.46% | |
| Below Lower BB | Weakness | -2.46% | |
| Down 3 Days in a Row | Weakness | -2.46% | |
| Lower Bollinger Band Touch | Weakness | -2.46% | |
| 20 DMA Resistance | Bearish | -6.67% | |
| Bollinger Band Squeeze | Range Contraction | -6.67% | |
| BB Squeeze + Lower Band Touch | Range Contraction | -6.67% |
| Alert | Time |
|---|---|
| Down 3% | about 5 hours ago |
| Down 2 % | about 5 hours ago |
| Down 1% | about 5 hours ago |
| Gap Up Closed | 1 day ago |
| Gap Up Partially Closed | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 03/14/2024
ImmunoPrecise Antibodies Ltd. Description
ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Immunology Antibodies Monoclonal Antibody Antibody Cloning Screening
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.39 |
| 52 Week Low | 0.95 |
| Average Volume | 721,257 |
| 200-Day Moving Average | 1.65 |
| 50-Day Moving Average | 1.40 |
| 20-Day Moving Average | 1.26 |
| 10-Day Moving Average | 1.26 |
| Average True Range | 0.09 |
| RSI (14) | 34.21 |
| ADX | 13.98 |
| +DI | 14.82 |
| -DI | 24.20 |
| Chandelier Exit (Long, 3 ATRs) | 1.11 |
| Chandelier Exit (Short, 3 ATRs) | 1.38 |
| Upper Bollinger Bands | 1.35 |
| Lower Bollinger Band | 1.16 |
| Percent B (%b) | -0.08 |
| BandWidth | 15.06 |
| MACD Line | -0.05 |
| MACD Signal Line | -0.05 |
| MACD Histogram | 0.0006 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.34 | ||||
| Resistance 3 (R3) | 1.35 | 1.29 | 1.31 | ||
| Resistance 2 (R2) | 1.29 | 1.24 | 1.29 | 1.30 | |
| Resistance 1 (R1) | 1.22 | 1.21 | 1.19 | 1.21 | 1.29 |
| Pivot Point | 1.16 | 1.16 | 1.14 | 1.16 | 1.16 |
| Support 1 (S1) | 1.09 | 1.11 | 1.06 | 1.08 | 1.01 |
| Support 2 (S2) | 1.03 | 1.08 | 1.03 | 1.00 | |
| Support 3 (S3) | 0.96 | 1.03 | 0.99 | ||
| Support 4 (S4) | 0.95 |
